Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults - Macaya Douoguih; Neil Goldstein; Stephan Bart; Kerstin Luhn; Wilbert Van Duijnhoven; Carla Truyers; Benoit Callendret (Journal of Virus Eradication, 2016)